Business

Inhaled drug developer Prosonix has announced a global licensing agreement with Mylan for its generic versions of GSK's Flixotide and Flovent fluticasone propionate MDIs for the treatment of asthma. The deal covers two Prosonix MDIs, PSX1001 and PSX1050, with the same particle engineered formulation of fluticasone; PSX1050 differs from PSX1001 only in having a dose … [Read more...] about Prosonix licenses two MDIs to Mylan

According to Hovione, the United States Patent and Trademark Office (USPTO) has granted the company a patent for its XCAPs capsule-based dry powder inhaler. The European Patent Office granted the company a patent for the inhaler in September, 2013. Hovione VP Peter Villax, who is a co-inventor of the DPI, commented, “We give our customers an edge in speed of … [Read more...] about Hovione gets US patent for XCaps inhaler

Swedish pharmaceutical company Meda has confirmed that Mylan approached the company with a takeover offer and that Meda rejected the offer. According to Meda, "All continued discussions between Meda and Mylan have been terminated without further actions." In June 2013, Meda denied that it was in talks to be acquired by Sun Pharmaceuticals. Meda's products … [Read more...] about Meda rejects Mylan offer

Swedish CDMO Recipharm, which has a dedicated DPI manufacturing facility in the UK, has begun trading on the Stockholm stock exchange, according to NASDAQ OMX. Recipharm had announced the IPO in March 2014. Recipharm CEO Thomas Eldered said, “Today marks the beginning of a new phase in Recipharm’s life. We welcome all our new shareholders who have demonstrated their … [Read more...] about Recipharm begins trading on Stockholm stock exchange

Skyepharma revenues were up 25% in 2013, the company said, in large part due to increased sales of its Flutiform fluticasone/formoterol MDI. The company also announced that it will seek to raise £112 million through a firm placing and a placing and open offer of over 58,680,000 ordinary shares at a price of 191 pence. Skyepharma CEO Peter Grant commented, "2013 … [Read more...] about Skyepharma revenues up on increased Flutiform sales, looks to raise £112 million

NanoBio has announced that Merck has acquired exclusive rights to NanoBio's NanoStat nanoemulsion adjuvant for an intranasal respiratory syncytial virus (RSV) vaccine. Merck also acquired non-exclusive rights to the adjuvant for use in an intranasal flu vaccine. The amount of the deal, which includes an upfront payment, milestone payments, and royalties on any sales … [Read more...] about Merck licenses adjuvant technology from NanoBio for intranasal RSV vaccine

Non-profit R&D organization Southwest Research Institute (SwRI) has announced that it has received a 28-month contract extension worth $8.3 million from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) for continued development of an intranasal isoamyl nitrite formulation for the treatment of cyanide … [Read more...] about BARDA awards $8.3 million to SwRI for intranasal isoamyl nitrite development

Vectura has announced that under a license agreement with "the US division of a leading international pharmaceutical company" signed in 2011, it has reached a milestone associated with the US development of its VR315 salmeterol/fluticasone DPI (known as AirFluSal Forspiro in Europe). According to the company, it received a payment of $10 million in August 2011 and … [Read more...] about Vectura gets additional milestone payment for development of VR315 in the US